GlassScriptPhysician profile
David P Rudman
NPI 1821026709
$1,221.72
in general payments reported to CMS, 2019-2025
15 companies · $515 in 2025
The $515 reported for 2025 was less than what a typical Orthopaedic Surgery provider received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $168 · 2020: $15.02 · 2021: $13.27 · 2022: $121 · 2023: $38.63 · 2024: $351 · 2025: $515.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $904.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $904.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $357.99 | 2022-2024 | Knotilus Anchor, 3.5mm, Iconix, Alphavent |
| Smith+Nephew, INC. | $315.07 | 2019-2025 | Aetos Shoulder System |
| Pacira Pharmaceuticals Incorporated | $120.29 | 2025 | Exparel |
| Seapearl East, INC | $97.63 | 2021-2025 | |
| Lifenet Health | $84.27 | 2025 | Graftlink |
| Janssen Biotech, INC. | $56.17 | 2025 | Tremfya |
| Ucb, INC. | $38.11 | 2024 | Cimzia, Bimzelx |
| Linkbio Corp | $37.07 | 2025 | |
| Alvogen INC | $18.06 | 2025 | Teriparatide |
| Cumberland Pharmaceuticals, INC. | $17.31 | 2024 | Caldolor |
| Ani Pharmaceuticals, INC. | $17.19 | 2024 | Purified Cortrophin Gel |
| Ferring Pharmaceuticals INC. | $17.00 | 2024 | Euflexxa |
| Sobi, INC | $16.54 | 2025 | |
| Intersect Ent, INC. | $15.02 | 2020 | |
| Medacta USA, INC. | $14.00 | 2025 | Gmk Sphere |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Rudman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.